Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:CYCN NASDAQ:LPTX NASDAQ:MBRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.75+2.3%$0.81$0.55▼$2.22$9.01M1.598,490 shs14,499 shsCYCNCyclerion Therapeutics$3.84-2.3%$3.22$1.03▼$8.48$17.02M1.7425,649 shs27,568 shsLPTXLeap Therapeutics$2.05$0.00▼$0.00$84.95M-0.0640.67 million shs760.56 million shsMBRXMoleculin Biotech$2.28-6.6%$2.57$1.79▼$24.00$13.02M1.751.12 million shs138,318 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+2.34%+0.54%-1.31%-18.74%-60.37%CYCNCyclerion Therapeutics-2.29%+11.95%+24.27%+31.96%+10.66%LPTXLeap Therapeutics0.00%0.00%0.00%0.00%+204,999,900.00%MBRXMoleculin Biotech-6.56%-13.64%-8.80%-12.98%-84.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.75+2.3%$0.81$0.55▼$2.22$9.01M1.598,490 shs14,499 shsCYCNCyclerion Therapeutics$3.84-2.3%$3.22$1.03▼$8.48$17.02M1.7425,649 shs27,568 shsLPTXLeap Therapeutics$2.05$0.00▼$0.00$84.95M-0.0640.67 million shs760.56 million shsMBRXMoleculin Biotech$2.28-6.6%$2.57$1.79▼$24.00$13.02M1.751.12 million shs138,318 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+2.34%+0.54%-1.31%-18.74%-60.37%CYCNCyclerion Therapeutics-2.29%+11.95%+24.27%+31.96%+10.66%LPTXLeap Therapeutics0.00%0.00%0.00%0.00%+204,999,900.00%MBRXMoleculin Biotech-6.56%-13.64%-8.80%-12.98%-84.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 2.40Hold$4.07445.86% UpsideCYCNCyclerion Therapeutics 1.00SellN/AN/ALPTXLeap Therapeutics 1.00SellN/AN/AMBRXMoleculin Biotech 2.33Hold$22.00864.91% UpsideCurrent Analyst Ratings BreakdownLatest LPTX, APRE, MBRX, and CYCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $6.005/7/2026APREAprea Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.004/29/2026CYCNCyclerion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026MBRXMoleculin Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026APREAprea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$290K31.80N/AN/A$1.52 per share0.49CYCNCyclerion Therapeutics$2.07M8.03N/AN/A$2.31 per share1.66LPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$4.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.60M-$1.54N/AN/AN/A-4,405.59%-61.03%-50.24%8/11/2026 (Estimated)CYCNCyclerion Therapeutics-$3.53M-$1.36N/AN/AN/A-170.11%-62.10%-55.14%8/4/2026 (Estimated)LPTXLeap Therapeutics-$67.56M-$1.22N/AN/AN/AN/A-247.44%-146.51%N/AMBRXMoleculin Biotech-$33.56M-$17.98N/AN/AN/AN/AN/A-70.93%8/11/2026 (Estimated)Latest LPTX, APRE, MBRX, and CYCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026N/ACYCNCyclerion Therapeutics-$7.10N/AN/AN/A$1.50 millionN/A5/14/2026Q1 2026MBRXMoleculin Biotech-$2.3333-$3.54-$1.2067-$3.54N/AN/A5/13/2026Q1 2026APREAprea Therapeutics-$0.23-$0.22+$0.01-$0.22$0.00 millionN/A5/12/2026Q1 2026CYCNCyclerion Therapeutics-$17.20-$0.76+$16.44-$0.76$0.88 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A8.928.92CYCNCyclerion TherapeuticsN/A1.801.80LPTXLeap TherapeuticsN/A1.341.34MBRXMoleculin BiotechN/A1.381.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%CYCNCyclerion Therapeutics75.62%LPTXLeap Therapeutics30.46%MBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics10.49%CYCNCyclerion Therapeutics34.30%LPTXLeap Therapeutics4.30%MBRXMoleculin Biotech1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics712.38 million11.08 millionNo DataCYCNCyclerion Therapeutics304.33 million2.85 millionNo DataLPTXLeap Therapeutics4041.44 million39.66 millionN/AMBRXMoleculin Biotech205.34 million5.28 millionNot OptionableLPTX, APRE, MBRX, and CYCN HeadlinesRecent News About These CompaniesMoleculin Biotech CEO Discusses Preliminary MIRACLE Trial Results for Annamycin in Virtual Investor SegmentJuly 6, 2026 | quiverquant.comQMoleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" SegmentJuly 6, 2026 | globenewswire.comMBRX stock drops 25% as Moleculin Biotech's interim cancer trial data falls short of significanceJuly 1, 2026 | msn.comWhy is Moleculin Stock Falling Today?June 30, 2026 | benzinga.comMoleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than ControlJune 30, 2026 | globenewswire.comMoleculin Biotech Insider Trading Activity | NASDAQ:MBRX | BenzingaJune 25, 2026 | benzinga.comIndependent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AMLJune 5, 2026 | globenewswire.comMoleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” SegmentJune 4, 2026 | globenewswire.comMoleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline LimitsMay 29, 2026 | globenewswire.comMoleculin Biotech Releases Updated Investor Information PresentationMay 26, 2026 | tipranks.comMoleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for AnnamycinMay 21, 2026 | globenewswire.comMoleculin Biotech Reports Promising Early Results in MIRACLE Trial for AML Treatment with 40% Composite Complete Remission RateMay 15, 2026 | quiverquant.comQMoleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE TrialMay 15, 2026 | globenewswire.comMoleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical BenchmarksMay 13, 2026 | globenewswire.comIndependent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline LimitsMay 12, 2026 | globenewswire.comMoleculin Biotech Secures Hong Kong Patent for Annamycin Method Ahead of Phase 3 Clinical Data ReleaseMay 8, 2026 | quiverquant.comQMoleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of AnnamycinMay 8, 2026 | globenewswire.comMoleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026April 24, 2026 | markets.businessinsider.comMoleculin Biotech, Inc. Reports Promising Preclinical Results for Annamycin in Pancreatic Cancer TreatmentApril 23, 2026 | quiverquant.comQMoleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026April 23, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLPTX, APRE, MBRX, and CYCN Company DescriptionsAprea Therapeutics NASDAQ:APRE$0.74 +0.02 (+2.34%) Closing price 07/10/2026 03:52 PM EasternExtended Trading$0.72 -0.02 (-2.68%) As of 07/10/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Cyclerion Therapeutics NASDAQ:CYCN$3.84 -0.09 (-2.29%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$3.80 -0.04 (-1.02%) As of 07/10/2026 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Leap Therapeutics NASDAQ:LPTXLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Moleculin Biotech NASDAQ:MBRX$2.28 -0.16 (-6.56%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$2.29 +0.01 (+0.44%) As of 07/10/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
